|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Earnings: Tough Times Ahead
Author(s)Kevin Gopal
Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.
Advertisement
Articles in this issue
over 24 years ago
Research: New Horizonsover 24 years ago
Outbreak: Anthrax Alarmover 24 years ago
Patents: China on the Genome Mapover 24 years ago
Privacy, Pediatrics, and Policyover 24 years ago
Lilly's International Familyover 24 years ago
Update: Punishment and Reprieveover 24 years ago
Shortage: Vaccine Worriesover 24 years ago
Gateway to Japanover 24 years ago
SurroundedNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
2
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
3
AI Built for Pharma—Out-of-the-Box Wins on Time, Risk, and ROI
4
FDA Announces New Biosimilar-Targeted Draft Guidance
5
